This webinar will focus on the use of the Chinese Hamster Ovary (CHO) system in the pharmaceutical industry. The CHO expression system is the most frequently used non-human mammalian cell line for developing and generating biological therapeutics. The CHO system is favored for its resilience to variations in growth conditions and resistance to infections. They can be grown to high densities making it possible to obtain recombinant protein expression at high yields.

In this webinar, the featured speaker will detail the differences between commonly used protein expression systems. In addition, attendees will learn why the CHO platform is preferred in drug discovery. This webinar will also be open to questions to discuss any other topics of interest related to this CHO platform.

Keywords:

Speaker

Ishita Barman, Sr. Field Application Scientist, GenScript USA Inc.

Ms. Barman has over 13 years of extensive hands-on experience in a broad range of molecular biology, expression and protein engineering skills. She has worked with therapeutic antibodies in biopharmaceutical companies like Pfizer and BMS, where she actively participated in early research and drug development. She is currently a Sr. Field Application Scientist with GenScript’s Life Sciences Group focusing on their protein and antibody portfolio. Ms. Barman holds a master’s degree in Molecular Biology from SJSU, a MS in Microbiology and a BS in Biological Sciences from MSU, India.

Message Presenter

Who Should Attend?

This webinar is recommended for anyone interested in recombinant protein expression technologies. While the webinar will go into some scientific detail, in general, all efforts will be made to make the presentation accessible to everyone.

What You Will Learn

A comparison of common protein expression systems
The history of the CHO platform in protein expression
How the CHO expression system can accelerate research involving proteins and antibodies

Xtalks Partner

GenScript

GenScript is the leading contract research organization in the world providing gene, peptide, protein, CRISPR, and antibody services. Since its foundation in 2002, GenScript has grown exponentially through partnerships with scientists conducting fundamental life science research, translational biomedical research, and early-stage pharmaceutical development. The company is recognized as having built a best-in-class capacity and capability for biological research services, encompassing gene synthesis, peptide synthesis, custom antibody and protein engineering, and in vitro and in vivo pharmacology — all with the goal to Make Research Easy.